EWTX Stock Summary and Trading Ideas (Edgewise Therapeutics | NASDAQ:EWTX)

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Edgewise Therapeutics trades on the NASDAQ stock market under the symbol EWTX.

As of November 3, 2026, EWTX stock price declined to $37.68 with 1,520,654 million shares trading.

EWTX has a beta of 1.09, meaning it tends to be more sensitive to market movements. EWTX has a correlation of 0.05 to the broad based SPY ETF.

EWTX has a market cap of $4.09 billion. This is considered a Mid Cap stock.

In the last 3 years, EWTX traded as high as $48.51 and as low as $5.12.

The top ETF exchange traded funds that EWTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

EWTX has outperformed the market in the last year with a price return of +106.1% while the SPY ETF gained +11.7%. However, in the short term, EWTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.0% vs +1.2% return in SPY. But in the last 2 weeks, EWTX shares have fared better than the market returning -0.6% compared to SPY -1.6%.

EWTX support price is $36.88 and resistance is $39.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EWTX shares will trade within this expected range on the day.